Acral Lentiginous Malignant Melanoma Clinical Trial
Official title:
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective SU011248 works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell.
- Participants will be given a bottle of SU011248 pills and will be asked to take pills
once daily for 28 days on an ongoing basis. Participants will return every 28 days for
new pills.
- During all treatment cycles, participants will have a physical exam and undergo blood
tests at every visit.
- After a month of receiving the study drug participants will undergo a repeat PET scan
to see if the drug has caused any early changes to their cancer.
- At week 8 a repeat chest, abdomen and pelvic CT will be performed.
- Participants will be on this research study for approximately one year.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01120275 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT00243061 -
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT01395121 -
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
|
Phase 2 | |
| Completed |
NCT00470470 -
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 |